{"analyses":[{"ciLowerLimit":"0.60","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.58","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.92","paramType":"Hazard Ratio (HR)","paramValue":"0.81","statisticalMethod":"Regression, Cox"},{"ciLowerLimit":"0.50","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1.38","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.55","paramType":"Hazard Ratio (HR)","paramValue":"0.83","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.1","upperLimit":"7.0","value":"4.0"},{"groupId":"OG001","lowerLimit":"2.1","upperLimit":"7.2","value":"4.6"},{"groupId":"OG002","lowerLimit":"1.8","upperLimit":"5.5","value":"3.3"},{"groupId":"OG003","lowerLimit":"1.5","upperLimit":"2.0","value":"1.8"},{"groupId":"OG004","lowerLimit":"1.3","upperLimit":"1.9","value":"1.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"9"}],"units":"Participants"}],"description":"Distributions are summarized using the Kaplan-Meier method. Median times for each therapy arm are accompanied by 90% confidence intervals based on log(-log(endpoint)) methodology. NSCLC: The pairwise comparisons between the durvalumab/tremelimumab alone and durvalumab/tremelimumab with RT arms will be conducted using Cox regression. CRC: No statistical comparisons conducted between Arms A and B.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive tremelimumab and durvalumab as in Arm C. Beginning at week 2, patients receive high-dose radiation therapy QD over 10 days for up to 3 fractions.\n\nDurvalumab: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTremelimumab: Given IV","id":"OG000","title":"NSCLC Arm A (Tremelimumab, Durvalumab, HD-RT)"},{"description":"Patients receive tremelimumab and durvalumab as in Arm C. Beginning at week 2, patients receive low-dose radiation therapy every 6 hours BID on weeks 2, 6, 10 and 14.\n\nDurvalumab: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTremelimumab: Given IV","id":"OG001","title":"NSCLC Arm B (Tremelimumab, Durvalumab, LD-RT)"},{"description":"Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses.\n\nDurvalumab: Given IV\n\nTremelimumab: Given IV","id":"OG002","title":"NSCLC Arm C (Tremelimumab, Durvalumab)"},{"description":"Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses. Beginning at week 2, patients receive high-dose radiation therapy QD over 10 days for up to 3 fractions.\n\nDurvalumab: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTremelimumab: Given IV","id":"OG003","title":"CRC Arm A (Tremelimumab, Durvalumab, HD-RT)"},{"description":"Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses. Beginning at week 2, patients receive low-dose radiation therapy every 6 hours BID on weeks 2, 6, 10 and 14.\n\nDurvalumab: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTremelimumab: Given IV","id":"OG004","title":"CRC Arm B (Tremelimumab, Durvalumab, LD-RT)"}],"paramType":"MEDIAN","populationDescription":"Patients receiving at least one regimen of protocol therapy.","reportingStatus":"POSTED","timeFrame":"From date of randomization until objective disease progression or death, whichever occurs first [up to 2 years]","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}